NURIX THERAPEUTICS, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
NURIX THERAPEUTICS, INC. (NRIX) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$263.70 million for the 12-month period ending 2025-11-30, per its 10-K filed 2026-01-28.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-01-28
- NURIX THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$263.70M.
- NURIX THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$193.30M.
- NURIX THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$143.95M.
- NURIX THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$180.36M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-11-30 | -$263.70M 10-K · filed 2026-01-28 |
| 2024-11-30 | -$193.30M 10-K · filed 2026-01-28 |
| 2023-11-30 | -$143.95M 10-K · filed 2026-01-28 |
| 2022-11-30 | -$180.36M 10-K · filed 2025-01-28 |
| 2021-11-30 | -$117.06M 10-K · filed 2023-02-09 |
| 2020-11-30 | -$63.78M 10-K · filed 2022-01-28 |
| 2019-11-30 | -$21.46M 10-K · filed 2022-01-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |